Next Article in Journal
Proteomic Analysis of the Effect of Inorganic and Organic Chemicals on Silver Nanoparticles in Wheat
Previous Article in Journal
Unveiling Mesenchymal Stromal Cells’ Organizing Function in Regeneration
Article Menu
Issue 4 (February-2) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2019, 20(4), 824; https://doi.org/10.3390/ijms20040824

Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

1
Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland
2
Department of Thoracic Surgery, Lower Silesian Centre of Lung Diseases, Wroclaw 53-439, Poland
3
Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland
4
Department of Physiotherapy, Wroclaw University School of Physical Education, Wroclaw 51-612, Poland
*
Author to whom correspondence should be addressed.
Received: 25 January 2019 / Revised: 10 February 2019 / Accepted: 12 February 2019 / Published: 14 February 2019
(This article belongs to the Special Issue PD-L1, A Master Regulator of Immunity)
Full-Text   |   PDF [1961 KB, uploaded 15 February 2019]   |  

Abstract

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. Methods: 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of CD274 (PD-L1) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). Results: PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (p < 0.0001) and in higher lymph node status (pN) (p = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (p = 0.0332) in adenocarcinoma (AC) only. Conclusions: PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group. View Full-Text
Keywords: PD-L1; Ki-67; TTF-1; p63; non-small cell lung cancer PD-L1; Ki-67; TTF-1; p63; non-small cell lung cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pawelczyk, K.; Piotrowska, A.; Ciesielska, U.; Jablonska, K.; Glatzel-Plucinska, N.; Grzegrzolka, J.; Podhorska-Okolow, M.; Dziegiel, P.; Nowinska, K. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. Int. J. Mol. Sci. 2019, 20, 824.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top